VRAX — Virax Biolabs Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapFalling Star

Annual income statement for Virax Biolabs, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	20-F	10-K	20-F	20-F	20-F
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0.009	0.156	0.006	0.012
Cost of Revenue
Gross Profit	0	-0.001	0.051	-0.053	0.008
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	1.73	5.74	6.65	6.17	6.41
Operating Profit	-1.73	-5.73	-6.5	-6.16	-6.4
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-1.75	-5.46	-6.74	-6.2	-5.93
Provision for Income Taxes
Net Income After Taxes	-1.75	-5.46	-6.74	-6.07	-5.03
Minority Interest
Net Income Before Extraordinary Items
Net Income	-1.71	-5.46	-6.73	-6.06	-5.02
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-1.71	-5.46	-6.73	-6.06	-5.02
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-37.6	-128	-79	-40.6	-12.6
Dividends per Share